Your doctor has prescribed for you a medicine called CRYSVITA (burosumab) to treat X-linked hypophosphataemia (XLH).

Please consult with your doctor for any questions relating to XLH or its management.
CRYSVITA should be given by injection by a trained healthcare provider. The dose is based on your body weight. Your doctor will work out the right dose for you.
You can find more information about CRYSVITA in the following resources. Copies can be requested from your doctor:

- CRYSVITA Consumer Medicine Information (CMI)
  - https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2021-CMI-02100-1&d=20220923172310101
- CRYSVITA starter guide for adults
- CRYSVITA starter guide for children
- CRYSVITA starter guide for parent & carers

IMPORTANT INFORMATION ABOUT YOUR CRYSVITA PRESCRIPTION

1. Pharmacy dispensing
   a. Your CRYSVITA prescription can be dispensed from a hospital pharmacy or a retail pharmacy as directed by your doctor
      i. The pharmacy must have an account with Health Care Logistics (HCL), so that they can order CRYSVITA for you.
      ii. Please provide the sheet *CRYSVITA® (burosumab) Instructions for Pharmacies* to your preferred pharmacy to check that they will be able to fulfil your prescription.
   b. Your pharmacy is unlikely to hold a regular supply of CRYSVITA, so you will need to give them a few days warning before your next dose is due so that they can order it in for you. *Speak to your pharmacist to work out the optimal way for this to be done on a regular basis.*
   c. CRYSVITA should be kept refrigerated – between 2-8°C.
   d. Please take your CRYSVITA dose directly to the health care practice where you will be receiving the injection.

Kyowa Kirin Australia Pty Ltd, 68 York Street, Sydney.
https://www.kyowakirin.com/australia/index.html.
Date of Preparation October 2022. KKAU-XLH-2209202
Report adverse events to pv.kkau.2r@kyowakirin.com

CRYSVITA® (BUROSUMAB) ACCESS INSTRUCTIONS FOR PHARMACIES

Dear Pharmacist,

Your patient has been prescribed CRYSVITA® (burosumab) for the treatment of X-linked hypophosphataemia.

CRYSVITA® is distributed by Healthcare Logistics (HCL) to pharmacies.

Healthcare Logistics
7 Dolerite Way, Pemulwuy, NSW, 2145
PO Box 6006, Seven Hills, NSW 2147
Tel -1300 364 586
Fax 1300 068 494
Email Client.Services@hcl.com.au

HCL account applications can be requested from Kyowa Kirin Australia or downloaded from https://hcl.com.au/

What is CRYSVITA®?

CRYSVITA® is a recombinant fully human monoclonal antibody (IgG1) that binds to and inhibits the excess activity of FGF23[1]

By inhibiting FGF23 activity, CRYSVITA® increases tubular reabsorption of phosphate from the kidney and increases serum concentration of $1,25(OH)_2D$, so increasing serum phosphate levels[1]

CRYSVITA® Indication

CRYSVITA® is indicated for the treatment of X-linked hypophosphataemia (XLH) in adults, adolescents and children 1 year of age or older1

CRYSVITA® PBS Listing[2]

Date of listing: 1 November 2022
Condition: X-linked hypophosphataemia
PBS Indication: X-linked hypophosphataemia
Category / program: Section 100 (Highly Specialised Drugs Program)
Authority Required: Telephone/online PBS Authorities system
Prescriber type: Medical Practitioners

CRYSVITA® - How Supplied[1]

- The product is available as one single-dose vial per carton in the following strengths: 10, 20, 30 mg/mL.
- Each pack contains 1 mL solution in a clear glass vial with butyl rubber stopper, and aluminium seal.

CRYSVITA® Storage[1]

- Visually inspect CRYSVITA® for particulate matter and discoloration prior to administration.
- CRYSVITA® is a sterile, preservative-free, clear to slightly opalescent and colourless to pale brown-yellow solution for subcutaneous injection.
- Do not use if the solution is discoloured or cloudy or if the solution contains any particles or foreign particulate matter

Store in original package to protect from light until use, under refrigerated conditions at 2°C to 8°C.

Do not freeze or shake. Do not use CRYSVITA® after the expiry date which is stated on the package and label. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Further information

Further information can be supplied on request from the manufacturer, Kyowa Kirin Australia.

Kyowa Kirin Australia Pty Ltd,
68 York Street, Sydney.
https://www.kyowakirin.com/australia/index.html.
Enquiries: enquiry.kkau@kyowakirin.com
Report adverse events to pv.kkau.2r@kyowakirin.com

PBS INFORMATION: This product is listed on the PBS as a Section 100 item.
Refer to PBS Schedule for full authority information.

Please refer to the Full Prescribing Information Available at: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2021-PI-02101-1&d=20220917172310101 Last accessed September 2022.

References:

1. Australian Product Information for Crysvita® (burosumab) approved Sept 2021. Available at: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2021-PI-02101-1&d=20220917172310101 Last accessed September 2022.
2. Australian Government. Schedule of Pharmaceutical Benefits. 2022. Available at: https://www.pbs.gov.au/pbs/home

Kyowa Kirin Australia Pty Ltd, 68 York Street, Sydney.
https://www.kyowakirin.com/australia/index.html.
Date of Preparation October 2022. KKAU-XLH-2209202
Report adverse events to pv.kkau.2r@kyowakirin.com